DIRECT new treatments for diabetic retinopathy

The Lancet

Volumn 372, Issue 9647, 2008, Pages 1361-1363

  Mitchell, Paul ^a   Wong, Tien Y ^b,c  

^a WESTMEAD HOSPITAL   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FENOFIBRATE; INDAPAMIDE; LISINOPRIL; PERINDOPRIL; PLACEBO;

ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; DIABETIC RETINOPATHY; GLYCEMIC CONTROL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; LOW LEVEL LASER THERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PRIORITY JOURNAL;

EID: 53749104339     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(08)61413-0     Document Type: Note

References (17)

1. Chaturvedi N., Porta M., Klein R., et al., for The DIRECT Programme Study Group. Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials. Lancet (2008) 10.1016/S0140-6736(08)61412-9 published online Sept 26.
2. Sjølie A.K., Klein R., Porta M., and for the DIRECT Programme Study Group. Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial. Lancet (2008) 10.1016/S0140-6736(08)61411-7 published online Sept 26.
3. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329 (1993) 977-986
4. Mohamed Q., Gillies M.C., and Wong T.Y. Management of diabetic retinopathy: A systematic review. JAMA 298 (2007) 902-916
5. Cheung N., and Wong T.Y. Diabetic retinopathy and systemic vascular complications. Progr Retin Eye Res 27 (2008) 161-176
6. Cheung N., Rogers S., Couper D.J., Klein R., Sharrett A.R., and Wong T.Y. Is diabetic retinopathy an independent risk factor for ischemic stroke?. Stroke 38 (2007) 398-401
7. Cheung N., Wang J.J., Klein R., Couper D.J., Sharrett A.R., and Wong T.Y. Diabetic retinopathy and the risk of coronary heart disease: the Atherosclerosis Risk in Communities Study. Diabetes Care 30 (2007) 1742-1746
8. Wong T.Y., Rosamond W., Chang P.P., et al. Retinopathy and risk of congestive heart failure. JAMA 293 (2005) 63-69
9. UK Prospective Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 317 (1998) 703-713
10. Sjolie A.K. Prospects for angiotensin receptor blockers in diabetic retinopathy. Diabetes Res Clin Pract 76 suppl 1 (2007) S31-S39
11. Chatervedi N., Sjolie A.K., Stephenson A.M., et al., the EUCLID Study Group. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. Lancet 351 (1998) 28-31
12. Schreier R.W., and Savage S. Appropriate blood pressure control in type II diabetes (ABCD trial): Implications for complications. Am J Kidney Dis 20 (1992) 653-657
13. ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 370 (2007) 829-840
14. Wong T.Y., Liew G., Tapp R., et al. Relation between fasting glucose and retinopathy for diagnosis of diabetes: three population-based cross-sectional studies. Lancet 371 (2008) 736-743
15. Wong T.Y., and Mitchell P. The eye in hypertension. Lancet 369 (2007) 425-435
16. Keech A.C., Mitchell P., Summanen P.A., et al., for the FIELD study investigators. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet 370 (2007) 1687-1697
17. Simo R., and Hernandez C. Fenofibrate for diabetic retinopathy. Lancet 370 (2007) 1667-1668